Archive for the ‘wrong reagents’ Category
Although they are confident that the strategy is sound, the authors write in their commendably detailed retraction notice that the “inadvertent error” rendered the results “uninterpretable.”
Authors of a 2010 Chemistry – A European Journal article have retracted it “due to the wrong assignment of structure” of catalysts.
The retraction is the third, by our count, for corresponding author Doo Ok Jang, a chemist at Yonsei University in Wonju. Jang authored one of the previously retracted papers with Sung Jun Kim and the other with Sang Yoon Kim. Both papers were also sunk by misassigned structures.
The current study, “Enantioselective Radical Addition to Ketimines: A Synthetic Route Towards α,α-Disubstituted α-Amino Acids,” is authored by all three chemists. Here’s the retraction notice:
The notice is clear on the problems with the science, which together “call into question the main conclusions of the paper.” Three of the paper’s five authors were employed at Novartis at the time of publication.
We’ve written before about how common cell line mix ups are in cancer research; according to a 2012 Wall Street Journal article (paywalled), between a fifth and a third of cancer cell lines tested by suspicious researchers turned out to be misidentified.
Obviously, mistakenly studying the wrong kind of cancer is a waste of precious resources, both time and money. And it’s clear the problem hasn’t gone away. PLoS ONE just retracted a cancer paper originally published in December 2012 for studying two cell lines that had been contaminated by other cell types.
Here’s the notice for “Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies:” Read the rest of this entry »
We’ve been following the case of Amine Bahi, a neuroscience researcher in the United Arab Emirates who has managed something unusual in the annals of Retraction Watch: Three different retractions for three completely different reasons. One was for “legal issues,” another was for lack of IRB approval, and the third was for using RNAs from the wrong species.
Now, Bahi’s co-authors have repeated the last of those studies with the right RNAs, and have republished their paper in the same journal, Biological Psychiatry — but without Bahi.
The retraction notice for “Blockade of Protein Phosphatase 2B Activity in the Amygdala Increases Anxiety- and Depression-Like Behaviors in Mice” now includes this final paragraph: Read the rest of this entry »
The article was titled “Oral Lactobacillus reuteri GMN-32 treatment reduces blood glucose concentrations and promotes cardiac function in rats with streptozotocin-induced diabetes mellitus.”
Robert Getzenberg, a former researcher at Hopkins and Pitt, has retracted a sixth paper, this one in Cancer Research.
Amine Bahi, a neuroscience researcher in the United Arab Emirates, has had a third paper retracted.
Here’s the notice for “Blockade of Protein Phosphatase 2B Activity in the Amygdala Increases Anxiety- and Depression-Like Behaviors in Mice,” which was posted on November 19: Read the rest of this entry »
About a month ago, we reported on a retraction by Pamela Ronald, of the University of California, Davis, and colleagues. We noted then that this was a case of scientists doing the right thing. Ronald contacted us after that post ran, and let us know that there would be another retraction shortly. That retraction notice has now appeared, in Science: Read the rest of this entry »